Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
37.14 USD | -0.55% | -1.01% | +92.72% |
11:51am | Baird Initiates Neurogene With Outperform Rating, $54 Price Target | MT |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.72% | 485M | |
+50.60% | 56.95B | |
+39.69% | 40.26B | |
-7.63% | 39.32B | |
-5.96% | 28.37B | |
+11.89% | 26.45B | |
-18.43% | 19.41B | |
+30.31% | 12.54B | |
+24.86% | 12.21B | |
-1.04% | 12.15B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target